Glycogen synthase kinase 3 inhibition promotes lysosomal biogenesis and autophagic degradation of the amyloid-β precursor protein

Molecular and Cellular Biology

Volumn 32, Issue 21, 2012, Pages 4410-4418

  Parr, Callum ^a   Carzaniga, Raffaela ^a   Gentleman, Steve M ^a   Van Leuven, Fred ^b   Walter, Jochen ^c   Sastre, Magdalena ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF LEUVEN   (Belgium)

^c UNIVERSITY OF BONN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID PRECURSOR PROTEIN; GLYCOGEN SYNTHASE KINASE 3ALPHA; GLYCOGEN SYNTHASE KINASE 3BETA; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR EB; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; AUTOPHAGY; CARBOXY TERMINAL SEQUENCE; ENZYME INHIBITION; LYSOSOME; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; ANTIBODIES, MONOCLONAL; AUTOPHAGY; BASIC HELIX-LOOP-HELIX LEUCINE ZIPPER TRANSCRIPTION FACTORS; BRAIN; CELL LINE, TUMOR; CHO CELLS; CRICETINAE; GLYCOGEN SYNTHASE KINASE 3; HEK293 CELLS; HUMANS; LYSOSOMES; MICE; PLAQUE, AMYLOID; RNA INTERFERENCE; RNA, SMALL INTERFERING;

EID: 84868687820     PISSN: 02707306     EISSN: 10985549     Source Type: Journal    
DOI: 10.1128/MCB.00930-12     Document Type: Article

References (43)

1. Aguib Y, et al. 2009. Autophagy induction by trehalose counteracts cellular prion infection. Autophagy 5:361-369.
2. Bhat R, et al. 2003. Structural insights and biological effects of glycogen synthase kinase 3-specific inhibitor AR-A014418 J. Biol. Chem. 278: 45937-45945.
3. Bhat RV, Budd Haeberlein SL, Avila J. 2004. Glycogen synthase kinase 3: a drug target for CNS therapies. J. Neurochem. 89:1313-1317.
4. Blalock EM, et al. 2004. Incipient Alzheimer's disease: microarray correlation analyses reveal major transcriptional and tumour suppressor responses. Proc. Natl. Acad. Sci. U. S. A. 101:2173-2178.
5. Boland B, et al. 2010. Macroautophagy is not directly involved in the metabolism of amyloid precursor protein. J. Biol. Chem. 285:37415- 37426.
6. Caccamo A, Oddo S, Tran LX, LaFerla FM. 2007. Lithium reduces tau phosphorylation but not A beta or working memory deficits in a transgenic model with both plaques and tangles. Am. J. Pathol. 170:1669 -1675.
7. Chan EYW, Kir S, Tooze SA. 2007. siRNA screening of the kinome identifies ULK1 as a multi-domain modulator of autophagy. J. Biol. Chem. 282:25464 -25474.
8. Feyt C, et al. 2005. Lithium chloride increases the production of amyloidbeta peptide independently from its inhibition of glycogen synthase kinas J. Biol. Chem. 280:33220 -33227.
9. Fleming A, Noda T, Yoshimori T, Rubinsztein DC. 2011. Chemical modulators of autophagy as biological probes and potential therapeutics. Nat. Chem. Biol. 7:9 -17.
10. Frame S, Zheleva D. 2006. Targeting glycogen synthase kinase-3 in insulin signalling. Expert Opin. Ther. Targets 10:429-444.
11. Fu L, et al. 2009. Perifosine inhibits mammalian target of rapamycin signaling through facilitating degradation of major components in the mTOR axis and induces autophagy. Cancer Res. 69:8967- 8976.
12. Heiseke A, Aguib Y, Riemer C, Baier M, Schätzl HM. 2009. Lithium induces clearance of protease resistant prion protein in prion-infected cells by induction of autophagy. J. Neurochem. 109:25-34.
13. Hooper C. 2007. Insulin signaling, GSK-3, heat shock proteins and the natural history of type 2 diabetes mellitus: a hypothesis. Metab. Syndr. Rel. Disord. 5:220 -230.
14. Hooper C, et al. 2007. Glycogen synthase kinase-3 inhibition is integral to long-term potentiation. Eur. J. Neurosci. 25:81- 86.
15. Inoki K, et al. 2006. TSC2 integrates Wnt and energy signals via a coordinated phosphorylation by AMPK and GSK3 to regulate cell growth. Cell 126:955-968.
16. Jaeger PA, et al. 2010. Regulation of amyloid precursor protein processing by the Beclin 1 complex. PLoS One 5:e11102. doi:10.1371/journal.pone.0011102.
17. Jope RS, Johnson GV. 2004. The glamour and gloom of glycogen synthase kinase-3. Trends Biochem. Sci. 29:95-102.
18. Katsouri L, Parr C, Bogdanovic N, Willem M, Sastre M. 2011. PPARγ co-activator-1α (PGC-1α) reduces amyloid-α generation through a PPARγ-dependent mechanism. J. Alz. Dis. 25:1-12.
19. Klionsky DJ, et al. 2008. Guidelines for the use and interpretation of assays for monitoring autophagy in higher eukaryotes. Autophagy 4:151- 175.
20. Mizushima N, Yoshimori T. 2007. How to interpret LC3 immunoblotting. Autophagy 3:542-545.
21. Nixon RA. 2007. Autophagy, amyloidogenesis and Alzheimer disease. J. Cell Sci. 20:4081- 4091.
22. Pei JJ, et al. 1997. Distribution, levels, and activity of glycogen synthase kinase-3 in the Alzheimer disease brain. J. Neuropathol. Exp. Neurol. 56:70 -78.
23. Phiel CJ, Wilson CA, Lee VM, Klein PS. 2003. GSK-3alpha regulates production of Alzheimer's disease amyloid-beta peptides. Nature 423: 435-439.
24. Rockenstein E, et al. 2007. Neuroprotective effects of regulators of the glycogen synthase kinase-3beta signaling pathway in a transgenic model of Alzheimer's disease are associated with reduced amyloid precursor protein phosphorylation. J. Neurosci. 27:1981-1991.
25. Rohatgi N, et al. 2010. Therapeutic strategies to increase human β-cell growth and proliferation by regulating mTOR and GSK-3/β-catenin pathways. Open Endocrinol. J. 4:40 -54.
26. Sardiello M, et al. 2009. A gene network regulating lysosomal biogenesis and function. Science 325:473- 477.
27. Sarkar S, et al. 2005. Lithium induces autophagy by inhibiting inositol monophosphatase. J. Cell Biol. 170:1101-1111.
28. Sarkar S, et al. 2008. A rational mechanism for combination treatment of Huntington's disease using lithium and rapamycin. Hum. Mol. Genet. 17:170 -178.
29. Sastre M, Turner RS, Levy E. 1998. X11 interaction with β-amyloid precursor protein modulates its cellular stabilization and reduces amyloid-β-protein secretion. J. Biol. Chem. 273:22351-22358.
30. Sastre M, et al. 2001. Presenilin-dependent gamma-secretase processing of beta-amyloid precursor protein at a site corresponding to the S3 cleavage of Notch. EMBO Rep. 2:835- 841.
31. Serenó L, et al. 2009. A novel GSK-3beta inhibitor reduces Alzheimer's pathology and rescues neuronal loss in vivo. Neurobiol. Dis. 35:359 -367.
32. Settembre C, Ballabio A. 2011. TFEB regulates autophagy: an integrated coordination of cellular degradation and recycling processes. Autophagy 7:1379 -1381.
33. Settembre C, et al. 2011. TFEB links autophagy to lysosomal biogenesis. Science 332:1429 -1433.
34. Su Y, et al. 2004. Lithium, a common drug for bipolar disorder treatment, regulates amyloid-beta precursor protein processing. Biochemistry 43: 6899-6908.
35. Sun X, et al. 2002. Lithium inhibits amyloid secretion in COS7 cells transfected with amyloid precursor protein C100. Neurosci. Lett. 321: 61- 64.
36. Takashima A, et al. 1996. Exposure of rat hippocampal neurons to amyloid beta peptide (25-35) induces the inactivation of phosphatidyl inositol-3 kinase and the activation of tau protein kinase I/GSK3beta. Neurosci. Lett. 203:33-36.
37. Tamboli IY, et al. 2011. Sphingolipid storage affects autophagic metabolism of the amyloid precursor protein and promotes Abeta generation. J. Neurosci. 31:1837-1849.
38. Terwel D, et al. 2008. Amyloid activates GSK-3beta to aggravate neuronal tauopathy in bigenic mice. Am. J. Pathol. 172:786 -798.
39. Tian Y, Bustos V, Flajolet M, Greengard P. 2011. A small-molecule enhancer of autophagy decreases levels of Abeta and APP-CTF via Atg5-dependent autophagy pathway. FASEB J. 25:1934 -1942.
40. Yang J, et al. 2010. GSK-3beta promotes cell survival by modulating Bif-1-dependent autophagy and cell death. J. Cell Sci. 123:861- 870.
41. Yu WH, et al. 2005. Macroautophagy-a novel beta-amyloid peptidegenerating pathway activated in Alzheimer's disease. J. Cell Biol. 171: 87-98.
42. Zhang Z, et al. 1998. Destabilization of beta-catenin by mutations in presenilin-1 potentiates neuronal apoptosis. Nature 395:698 -702.
43. Zhou F, van Laar T, Huang H, Zhang L. 2011. APP and APLP1 are degraded through autophagy in response to proteasome inhibition in neuronal cells. Protein Cell 2:377-383.